KYMR (Kymera Therapeutics) Ending Cash Position: $130.3 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KYMR Kymera Therapeutics Inc KYMR
48 GF Score
Price $117.29
GF Value $41.42
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Kymera Therapeutics Ending Cash Position?

Kymera Therapeutics KYMR -0.67% 48 Ending Cash Position is $130.3 Mil as of Jun. 2026. GuruFocus rates KYMR with a GF Score™ of 48/100 and a GF Value™ of $41.42 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Kymera Therapeutics's Ending Cash Position for the quarter that ended in Jun. 2026 was $130.3 Mil.

Kymera Therapeutics's quarterly Ending Cash Position declined from Dec. 2025 ($362.8 Mil) to Mar. 2026 ($149.9 Mil) and declined from Mar. 2026 ($149.9 Mil) to Jun. 2026 ($130.3 Mil).

Kymera Therapeutics's annual Ending Cash Position increased from Dec. 2023 ($115.8 Mil) to Dec. 2024 ($126.1 Mil) and increased from Dec. 2024 ($126.1 Mil) to Dec. 2025 ($362.8 Mil).

Kymera Therapeutics Ending Cash Position Related Terms

Kymera Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Kymera Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kymera Therapeutics Ending Cash Position Chart

Kymera Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 54.09 74.53 115.78 126.05 362.81

Kymera Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 341.64 118.74 362.81 149.90 130.30
KYMR
48GF Score
Kymera Therapeutics Inc KYMR
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kymera Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Kymera Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=126.05+236.761
=362.8

Kymera Therapeutics's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=149.9+-19.601
=130.3

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $130.3 Mil mean?
Kymera Therapeutics (KYMR) has a Ending Cash Position of $130.3 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Kymera Therapeutics and its competitors.
Is Kymera Therapeutics' Ending Cash Position too high?
Kymera Therapeutics' current Ending Cash Position is $130.3 Mil. Overall, Kymera Therapeutics has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kymera Therapeutics' Ending Cash Position compare to PRAX and CYTK?
Kymera Therapeutics' Ending Cash Position of $130.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Kymera Therapeutics and its competitors. Kymera Therapeutics's current Ending Cash Position is $130.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kymera Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Kymera Therapeutics (KYMR) is currently considered Significantly Overvalued. The stock's GF Value™ is $41.42, compared to a current price of $117.29 — trading 183.2% above its estimated fair value. The current Ending Cash Position is $130.3 Mil. Kymera Therapeutics' overall GF Score™ is 48/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Kymera Therapeutics (KYMR), the current Ending Cash Position is $130.3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kymera Therapeutics (KYMR) Overvalued in 2026?

Based on GuruFocus' analysis, Kymera Therapeutics stock appears to be overvalued. The current stock price of $117.29 is trading 183.2% above its estimated GF Value™ of $41.42. GuruFocus considers Kymera Therapeutics to be Significantly Overvalued.

Key valuation signals for KYMR:

  • Ending Cash Position: $130.3 Mil
  • GF Value™: $41.42 vs. price of $117.29 (183.2% above fair value)
  • GF Score™: 48/100 with 8 warning signs

No single metric tells the full story. See the KYMR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kymera Therapeutics Business Description

Address 500 North Beacon Street, 4th Floor, Watertown, MA, USA, 02472
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
48GF Score

Get the complete analysis for KYMR

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$117.29
Price
$41.42
GF Value